DeepMed Research

Insel Gruppe AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 2016-01-01

Employees: 10K

Market Cap: -

Website: https://www.inselgruppe.ch

Clinical Trials

Pedometer Activity Monitoring After ASCT

Phase 2

Completed

Conditions: High-dose Chemotherapy
Myeloma
Lymphoma
Autologous Stem Cell Transplantation

Interventions: Behavioral: Pedometer-based activity monitoring after ASCT

First Posted Date: 2017-08-03

Last Posted Date: 2023-04-03

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 62

Registration Number: NCT03238599

Locations: 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin

Phase 2

Terminated

Conditions: Muscle-invasive Bladder Cancer

Interventions: Drug: Durvalumab (Imfinzi)
Drug: Tremelimumab

First Posted Date: 2017-07-31

Last Posted Date: 2020-06-17

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 6

Registration Number: NCT03234153

Locations: 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland

GLOBAL LEADERS Adjudication Sub-Study

Completed

Conditions: Coronary Artery Disease
Platelet-aggregation Inhibitors

First Posted Date: 2017-07-27

Last Posted Date: 2020-08-03

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 7365

Registration Number: NCT03231059

Locations: 🇦🇹
Wilhelminenspital 1160, Vienna, Austria
🇧🇪
Research centre Hasselt 3203, Hasselt, Belgium
🇧🇬
Research centre Sofia, 9901, Sofia, Bulgaria

and more 16 locations

Normative Database for HR-pQCT-Based Radius and Tibia Strength

Conditions: Fracture
Osteoporosis
Bone Strength
Diagnoses Disease

First Posted Date: 2017-07-17

Last Posted Date: 2018-10-23

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 576

Registration Number: NCT03219099

Locations: 🇨🇭
University Hospital Inselspital, Bern, Switzerland

Surgical Pulmonary Embolectomy Versus Catheter-directed Thrombolysis in the Treatment of Pulmonary Embolism: A Non-inferiority Study

Not Applicable

Completed

Conditions: Acute Pulmonary Embolism (PE)

Interventions: Procedure: surgical pulmonary embolectomy
Combination Product: catheter-directed thrombolysis

First Posted Date: 2017-07-14

Last Posted Date: 2021-11-23

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 60

Registration Number: NCT03218410

Locations: 🇨🇭
University Hospital Bern, Bern, Switzerland

Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke

Not Applicable

Completed

Conditions: Ischemic Stroke

Interventions: Device: Stent-retriever thrombectomy with revascularization device of the Solitaire™ type
Drug: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)

First Posted Date: 2017-06-20

Last Posted Date: 2024-11-14

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 410

Registration Number: NCT03192332

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Canada
🇫🇷
CHU Tours, Tours, France
🇨🇦
Mc Gill University, Montréal, Canada

and more 45 locations

Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas

Phase 1

Suspended

Conditions: Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: BeEAM Regimen

First Posted Date: 2017-06-14

Last Posted Date: 2025-03-30

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 20

Registration Number: NCT03187210

Locations: 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland

Bendamustine and Melphalan in Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Melphalan
Drug: Bendamustine

First Posted Date: 2017-06-14

Last Posted Date: 2025-01-30

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 120

Registration Number: NCT03187223

Locations: 🇨🇭
Department for Medical Oncology University Hospital/Inselspital, Berne, Switzerland

Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis

Completed

Conditions: Drug-Eluting Stents
Tomography, Optical Coherence
Coronary Thrombosis

Interventions: Device: Bioresorbable vascular scaffold

First Posted Date: 2017-06-08

Last Posted Date: 2017-10-30

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 36

Registration Number: NCT03180931

Locations: 🇦🇹
5th Medical Department with Cardiology, Kaiser Franz Josef Hospital, Vienna, Austria
🇫🇷
Department of Cardiology, University Hospital Caremeau, Nimes, France
🇫🇷
Department of Cardiology, CH F Mitterand, Pau Université Cedex, France., Pau, France

and more 16 locations

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

Not Applicable

Completed

Conditions: Ischaemic Stroke

Interventions: Drug: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Drug: Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)

First Posted Date: 2017-05-11

Last Posted Date: 2023-07-18

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 2013

Registration Number: NCT03148457

Locations: 🇦🇹
Universitätsklinikum Tulln, Tulln, Austria
🇮🇳
All India Institute Of Medical Sciences, New Delhi, Delhi, India
🇦🇹
Medizinische Universität Graz, Graz, Austria

and more 95 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy